Abstract
We assessed the efficacy, safety and convenience of salmeterol (SLM)/fluticasone propionate (FP) combination (SFC) in children with asthma. Subjects were children aged 5 to 14 years. Efficacy population consisted of 48 patients, 32 male and 16 female patients who had mild persistent asthma (11 patients) or moderate persistent asthma (37 patients). The mean age was 8.4 years. Each subject received the two treatments SFC 25/50μg (one inhalation twice daily by pMDI) and SLM 25μg plus FP 50μg (each one inhalation twice daily by DPI) in a two-way crossover. Both treatments showed statistically significant improvements in morning PEF and the improvements were not statistically different. In the assessment of convenience, SFC was rated higher compared with SLM+FP, suggesting high adherence to SFC in clinical settings.
